Adverse reactions to radiopharmaceuticals are still not reported worldwide. However, the type of reaction may be severe and cause death. A review of the literature was performed using some criteria of a systematic review established by the Cochrane Collaboration. The results showed that there are a large number of adverse reactions to radiopharmaceuticals. Nuclear medicine staff must be aware of the possibility of adverse reaction with radiopharmaceuticals and find time to share this information with the radiopharmacist and the national pharmacovigilance system.
Introduction
Lazarou and coworkers 1 state that there is a high level of underreporting of suspect adverse drug reactions (ADRs), a condition that caused over 2341 deaths in the United States from 1999 to 2006. 2 Epidemiologic data on adverse drug reactions are sparse and generally old, and most studies were performed 10 to 30 years ago and were relatively restricted, often confined to individual units such as those for care of the elderly. 3, 4 Jones had already alerted to the fact that although ADRs can appear as isolated, specific clinical events that may be related to a number of factors in the patient's background and environment, in many situations it may not appear early as a detectable clinical event, but rather be clinically silent. 5 In any discussion on adverse reactions to radiopharmaceuticals, it is frequently difficult to define what constitutes an adverse reaction. 6 The US FDA defines it as "any adverse event associated with the use of a drug in humans, whether or not considered drug related, including the following: an adverse event occurring in the course of the use of drug product in professional practice; an adverse event occurring from drug overdose, whether accidental or intentional; an adverse event occurring from drug withdrawal; and any significant failure of expected pharmacologic action." 7, 8 Unlike drugs given for therapeutic purposes, radiopharmaceuticals rarely cause adverse reactions. This safety can be explained by the usually very small mass of drug injected or ingested, and also by the fact that radiopharmaceuticals are typically administered only once or a very limited number of times to any given patient. 8 Nevertheless, the possibility of adverse reaction to an administered radiopharmaceutical does exist. 9, 10 According to Silberstein and Ryan, 8 significant adverse drug reaction that should be reported must include (1) untoward effects whether observed frequently or rarely; (2) untoward effects never before seen following administration of the radiopharmaceutical; (3) only life-threatening or fatal reactions from drugs other than radiopharmaceuticals; (4) reactions unanticipated from unknown pharmacologic action of a nonradioactive pharmaceutical; and (5) anaphylactoid or allergic reactions.
Estimates of adverse reaction prevalence are difficult to assess, partly because of physician/doctor ignorance of available reporting schemes. The reasons for not filling out adverse reactions reporting forms are many, among them are the reactions' subjective aspect and of physician's anxiety about potential liability or belief that the reaction is common knowledge. 4, 6, 11 
Materials and Methods
A review of the literature on drug interaction with radiopharmaceuticals was carried out, using some systematic review criteria. 12 Computerized databases for radiopharmaceuticals were searched, such as MEDLINE, EMBASE, and the International Pharmaceutical Abstracts and Science Citation Index, published between 1956 and 2016, using "radiopharmaceuticals/drug interactions," "radiopharmaceuticals/interactions," and many others as keywords. The searches were supplemented with manual searches of bibliographies of the published articles on major radiopharmacy textbooks, and in the Cochrane Database of Systematic Review. The present review of the literature uses a selection of the collected material. Controlled trials, cohort studies, case-control studies, and case series in English, French, German, and Portuguese were considered. The difficulty to find studies related to radiopharmaceutical-drug interaction forced the acceptance of low-quality studies (with fewer than 10 reported cases), but those provided information not found in other literature. Besides, criteria included analyses of all study reports on prospective or retrospective monitoring of drug interaction with radiopharmaceuticals. All the papers were retrieved and reviewed.
Review

Technetium-Adverse Reaction
After the striking article by Hladik et al, 13 a paper by Spicer et al, 14 published in the Journal of Nuclear Medicine, described a true adverse allergic reaction to technetium-99m. According to the authors, a 60-year-old white female had a comedo-type ductal carcinoma of the breast in 1980, which resulted in a left mastectomy. By April 1983, multiple lung metastases were apparent on a chest radiograph. On April 4, 1983, she underwent a bone scan with MDP (methylene diphosphonate associated with Tc-99m), which revealed multiple metastases to thoracic and lumbar spine and right ischium. Forty-eight hours later, she had a scratchy sore throat and a pruritic, raised, erythematous rash that persisted for 3 to 4 days. On February 16, 1984, a new MDP bone scan was performed showing new metastatic lesions in bone. Forty-eight hours later she developed a sore throat and a generalized maculopapular rash that was pruritic and erythematous. She was found to have conjunctivitis and a hyperemic ulcerated pharynx consistent with the diagnosis of erythema multiforme. It was also noted that the patient had been on several chemotherapy drugs and had whole brain irradiation without any report of reaction.
The observed time delay (48 hours postinjection) is consistent with the report of Cordova et al, 15 Sampson, 5 Silberstein and coworkers, 16 Hesselwood and Keeling, 9 and Silberstein 11 indicating a 4 to 24 hours and sometimes longer time lag before the development of rash. The rash development for MDP was also the most common allergic reaction reported for MDP. It can be corroborated by Sampson 6 when he states that the most commonly used diphosphonate, MDP, accounts for the most adverse reaction to radiopharmaceuticals, but this may be due to the fact that bone scanning is the most common single nuclear medicine procedure. Among the symptoms of the use of MDP are dermographism, nausea, malaise, vertigo, and pruritus.
A severe systemic reaction to MDP was described by Balan and coworkers. 17 According to the authors, a 42-year-old woman with a history of recurrent breast cancer was injected with 555 MBq (15 mCi) of MDP. Twenty-four hours later, the patient felt unwell. Puffiness developed around the eyes, together with an erythematous skin rash on the trunk and around the eyes. Biochemical tests at that time, compared with those before the bone scan, suggested abnormal liver and kidney function; however, an ultrasound scan showed no alterations in both organs. The patient responded to a regime of intravenous fluids and corticosteroids, with a return to normal renal function 15 days after the bone scan and to normal liver function another 6 days later. The dermatologic manifestations resolved within 1 week. This case confirmed the other case described above and showed that adverse reactions related to radiopharmaceuticals do occur and can be very severe.
One case recently reported by Chicken and coworkers 18 involved an 80-year-old woman with a 4-month history of a left breast lump. Past medical history included an untreated allergic rhinitis. She reported allergy to penicillin but not to other drugs or plasters. She was administered nanocolloidal albumin (reconstituted under sterile conditions in the hospital's radiopharmaceutical laboratory according to the manufacturer's instructions and labelled with 14.4 MBq of technetium99m). A volume of 0.2 mL of the radiocolloid was intradermally injected overlying the tumor. After 1 hour of the injection, the patient reported itching over the breast and axilla. On examination, a raised urticarial rash was noted over the upper half of the breast extending from the injection site to the axilla. No drop in blood pressure or oxygen saturation was found clinically. A topical steroid cream was applied, with rapid resolution of both itching and rash within 30 minutes. A history of hypersensitivity to human albumin products is a contraindication to the injection of nanocolloidal albumin, and this important clinical information is easily overlooked. An anaphylactic reaction to Tc-99m sestamibi was described by Mujtaba. 19 According to the authors a 63-yearold white woman was injected at rest with 10 mCi (370 MBq) of Tc-99m sestamibi. Immediately after the application, acute shortness of breath and generalized itching developed. Examination revealed tachypnea, painless macroglossia, wheezing in bilateral lung fields, and a nonblanching pruritic maculopapular rash. All these symptoms were presumptive of anaphylactic reaction, and intravenous epinephrine and diphenhydramine were administered, with immediate results. This is the second case (the first was described by Thomson and Allman 20 and related erythema multiforme as an adverse reaction to Tc-99m sestamibi) described in the literature of anaphylactic reaction to Tc-99m sestamibi. This data is corroborated by Laroche and coworkers. 4 In the study from Laroche and coworkers 4 a pharmacovigilance study from 1989 to 2013 has been done. Their results reached 304 reports of adverse reaction to radiopharmaceuticals, with 12 deaths. Most of the cases were related to both types of radiopharmaceuticals (therapeutics and diagnostic ones). The average age of the patients that showed adverse reaction was 58 years and most of them were female (54.6%).
Adverse Reaction to Fluorodeoxyglucose (FDG)
In recent years, PET scans with FDG have been playing an increasingly important role in the evaluation of the response to induction chemotherapy, as well as in the detection of primary tumor and metastatic lesions in several malignancies. [21] [22] [23] In one reported case, a 66-year-old man was referred to the hospital for investigation of an abnormal shadow measuring 5.2 cm in diameter in the left upper lung field on a chest radiograph. The patient was eventually diagnosed with lung cancer classified as clinical stage IIIA (T2N2M0) and underwent induction chemotherapy with paclitaxel.
On the other hand, an FDG-PET scan prior to the chemotherapy demonstrated accumulation only in the tumor and not in the mediastinal node. This result led to suspicion that the disease had progressed to N3 lesions. Hence, the patient underwent a biopsy of the right supraclavicular lymph node and the mediastinal lymph nodes by mediastinoscopy. All dissected lymph nodes showed sarcoid reactions, and no tumor cells were found to be pathological. The patient had no clinical symptom of sarcoid, and the chest radiograph did not show streaks and/or spots. The conclusion was that a sarcoid reaction of the mediastinal lymph nodes probably led to the abnormal accumulation of FDG without tumor metastasis. Therefore, in patients with FDG-PET positive results, it is necessary to verify lymph node pathologically using mediastinoscopy, because this type of adverse reaction (sarcoid reaction) may occur and change the clinical conduction. 22 Another case of sarcoid reaction occurred with a 57-year-old female patient with a history of diffuse large B-cell lymphoma, involving the lungs and spleen. This patient received 8 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and rituximab (Rituxan) therapy. After 4 months, she underwent a PET-CT scan that showed increased uptake in the spleen. This patient underwent a splenectomy because of the suspicion of recurrence. The results of the pathological tests showed noncaseating granulomas consistent with sarcoid-like reaction.
These 2 cases show the importance of the sarcoid reaction and the importance of a pathological analysis in case of suspicion. 24 In a case report published by Han and coworkers, 25 an allergic reaction mimicked lymphoma on FDG PET/CT after contact with ginkgo nut with reactive hyperplasia on axillary lymph node. On the study of Laroche and coworkers, 4 
False-Positive Reactions
Another case of false-positive uptake, described by Iwasaki and coworkers 27 with a 57-year-old woman, demonstrated that fused FDG-PET and PET/CT images performed to analyze pulmonary suture abscess can be confused with lung cancer, because the abscess, as an inflammatory process, increase the uptake of FDG by the lesion. During the analysis, the scan data can be misunderstood as a lung cancer. A report made by Aide and coworkers 28 described a false-positive uptake of FDG in 3 patients related to foreign body reaction. According to the authors, remote mesh prostheses can induce FDG uptake because of persistent foreign body reaction. Consequently, in each scan an unexpected pelvic focus was noticed on FDG PET, since that is where the prostheses were. The authors confirmed that the medical history of patients should be carefully reviewed to avoid false positive results.
Hurwitz 29 described a 54-year-old woman with a treated carcinoma of the breast. There was spontaneous rupture of an implant placed previously as part of breast reconstruction. An FDG-PET scan was carried out and disclosed intense uptake in these nodes. Lymph node biopsy, however, demonstrated benign inflammatory reaction and no recurrence of malignancy. A false-positive PET scan may occur when FDG is taken up in a ruptured breast implant, and data should be carefully analyzed in these cases.
Another case of false-positive response was described by Modi and coworkers 30 in a 73-year-old man who received Teflon to treat a vocal cord paresis and showed abnormal uptake of FDG during a PET scan. According to the authors, the false-positive response was due to a foreign body reaction (as described above) related to Teflon.
An important case of false-positive reaction is related to the hip arthroplasty. A retrospective and prospective study conducted by Zhuang and coworkers 31 with 9 patients and 710 patients, respectively, concluded that, following hip arthroplasty, nonspecifically increased FDG uptake around the head or neck of the prosthesis persists for many years, even in patients without any complications. Therefore, to minimize the number of false-positive results with PET studies, caution should be exercised when interpreting FDG uptake around the head or neck portion of prostheses.
Recently, a study from Chism and coworkers 32 reported an increased 18 F-FDG uptake related to surgical mesh in a patient who had undergone vertical banded gastroplasty, corresponding to false-positive PET scan.
Statistical Database
After all the reported cases described above, a great number of studies were developed to ascertain the actual incidence of adverse reactions to radiopharmaceuticals. Silberstein and Ryan, 8 studying a total of 783,525 injections of radiopharmaceuticals in a prospective 5-year study, found 18 adverse reactions to radiopharmaceuticals. None was severe enough to cause hospitalization. It means that adverse reactions to radiopharmaceuticals are quite uncommon, occurring with a prevalence of 2.3/10 5 (0.0023%). The 95% confidence limits for these reactions are 0.1 to 11.7 per 100,000 injections. The study also verified the interventional pharmaceuticals (not tracers) used in nuclear medicine and found a prevalence of 5.9/10 5 , which means that they are also quite safe. An interesting aspect of this study was that 10 of the 18 adverse reactions reported were rashes. This may signify that most adverse reactions are in truth of the allergic type, or to be more specific, type I reactions as described by Sampson. 6 Their effects were generally mild and self-limiting and none was sufficiently serious to require hospital admission.
A second study conducted by Hesselwood 8 However, the effects noted were generally mild and self-limiting, and none was sufficiently serious to require admitting the patient to a hospital, like those Silberstein and Ryan 8 had noted. The same value was found by Laroche and coworkers. 4 The results of the 27th Report on Survey of Adverse Reaction to Radiopharmaceutical 33 were based on responses to questionnaires sent to nuclear medicine institutions. Among the 1220 institutions contacted, 968 replied. Sixteen cases of adverse reactions were reported. A total of 1,277,906 radiopharmaceutical administrations were reported. The incidence of adverse reactions per 100,000 cases was 1.3 (95% confidence limits: 3-15).
Conclusion
Adverse reactions to radiopharmaceuticals should be better documented and reported. This information should be disseminated worldwide.
The literature on this topic shows that just few studies were made in this direction and the amount of radiopharmaceuticals in use nowadays is so great that it seems impossible that the few reported cases were all that truly happened.
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